Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Kadmon Holdings (NASDAQ:KDMN) Share Price

Media stories about Kadmon Holdings (NASDAQ:KDMN) have been trending somewhat positive on Saturday, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Kadmon Holdings earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.787601814059 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

KDMN has been the topic of several recent research reports. Piper Jaffray Companies restated a “buy” rating and issued a $7.00 price target on shares of Kadmon Holdings in a research report on Friday, July 14th. ValuEngine cut Kadmon Holdings from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 1st. WBB Securities cut Kadmon Holdings from a “hold” rating to a “sell” rating and set a $3.00 price target on the stock. in a research report on Monday, October 9th. Finally, Zacks Investment Research cut Kadmon Holdings from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. Kadmon Holdings presently has an average rating of “Hold” and an average price target of $9.80.

Shares of Kadmon Holdings (NASDAQ:KDMN) traded down 0.57% during midday trading on Friday, hitting $3.49. The stock had a trading volume of 282,914 shares. The firm has a 50 day moving average of $3.43 and a 200-day moving average of $3.43. The company’s market cap is $180.94 million. Kadmon Holdings has a one year low of $2.86 and a one year high of $7.10.

Kadmon Holdings (NASDAQ:KDMN) last posted its quarterly earnings results on Thursday, August 3rd. The company reported ($0.44) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.05. The business had revenue of $3.00 million for the quarter, compared to the consensus estimate of $3.46 million. The company’s quarterly revenue was down 53.1% on a year-over-year basis. During the same period last year, the firm earned ($4.40) earnings per share. On average, analysts forecast that Kadmon Holdings will post ($1.55) earnings per share for the current fiscal year.

In other Kadmon Holdings news, major shareholder Goldentree Asset Management Lp sold 302,950 shares of the company’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $2.73, for a total value of $827,053.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last three months, insiders have purchased 14,707 shares of company stock valued at $34,294.

TRADEMARK VIOLATION NOTICE: This article was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at

About Kadmon Holdings

Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.

Insider Buying and Selling by Quarter for Kadmon Holdings (NASDAQ:KDMN)

Receive News & Ratings for Kadmon Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc and related companies with's FREE daily email newsletter.

Leave a Reply